Background: Hemodialysis (HD) patients have a greatly increased risk of cardiovascular morbidity and mortality. For this reason, attempts are often made to normalize hyperhomocysteinemia. This randomized prospective study sought to determine which risk factors are predictors of mortality and whether high doses of folates or 5-methyltetrahydrofolate (5-MTHF) could improve hyperhomocysteinemia and survival in HD patients. Methods: 341 patients were divided into two groups: group A was treated with 50 mg i.v. 5-MTHF, and group B was treated with 5 mg/day oral folic acid. Both groups received i.v. vitamin B6 and B12. By dividing patients into C-reactive protein (CRP) quartiles, group A had the highest survival for CRP <12 mg/l, whereas no survival difference was found for group B. CRP was the only predictive risk factor for death (RR 1.17, range 1.04-1.30, p = 0.02). Dialysis age, hyperhomocysteinemia, methylenetetrahydrofolate reductase polymorphism, albumin, lipoprotein (a) and folate did not influence mortality risk. Survival in group A was higher than that in group B, namely 36.2 ± 20.9 vs. 26.1 ± 22.2 months (p = 0.003). Results: Our results suggest that CRP, but not hyperhomocysteinemia, is the main risk factor for mortality in HD patients receiving vitamin supplements. Intravenous 5-MTHF seems to improve survival in HD patients independent from homocysteine lowering.

5-Methyltetrahydrofolate administration is associated with prolonged survival and reduced inflammation in ESRD patients / G. Cianciolo, G. La Manna, L. Colì, G. Donati, F. D'Addio, E. Persici, G. Comai, M. Wratten, A. Dormi, V. Mantovani, G. Grossi, S. Stefoni. - In: AMERICAN JOURNAL OF NEPHROLOGY. - ISSN 0250-8095. - 28:6(2008), pp. 941-948.

5-Methyltetrahydrofolate administration is associated with prolonged survival and reduced inflammation in ESRD patients

F. D'Addio;
2008

Abstract

Background: Hemodialysis (HD) patients have a greatly increased risk of cardiovascular morbidity and mortality. For this reason, attempts are often made to normalize hyperhomocysteinemia. This randomized prospective study sought to determine which risk factors are predictors of mortality and whether high doses of folates or 5-methyltetrahydrofolate (5-MTHF) could improve hyperhomocysteinemia and survival in HD patients. Methods: 341 patients were divided into two groups: group A was treated with 50 mg i.v. 5-MTHF, and group B was treated with 5 mg/day oral folic acid. Both groups received i.v. vitamin B6 and B12. By dividing patients into C-reactive protein (CRP) quartiles, group A had the highest survival for CRP <12 mg/l, whereas no survival difference was found for group B. CRP was the only predictive risk factor for death (RR 1.17, range 1.04-1.30, p = 0.02). Dialysis age, hyperhomocysteinemia, methylenetetrahydrofolate reductase polymorphism, albumin, lipoprotein (a) and folate did not influence mortality risk. Survival in group A was higher than that in group B, namely 36.2 ± 20.9 vs. 26.1 ± 22.2 months (p = 0.003). Results: Our results suggest that CRP, but not hyperhomocysteinemia, is the main risk factor for mortality in HD patients receiving vitamin supplements. Intravenous 5-MTHF seems to improve survival in HD patients independent from homocysteine lowering.
5-Methyltetrahydrofolate; C-reactive protein; ESRD patients; ESRD, survival; Homocysteine; Aged; C-Reactive Protein; Female; Humans; Hyperhomocysteinemia; Kidney Failure, Chronic; Male; Middle Aged; Models, Biological; Risk; Risk Factors; Tetrahydrofolates; Vitamin B 12; Vitamin B 6; Inflammation; Nephrology
Settore MED/13 - Endocrinologia
2008
Article (author)
File in questo prodotto:
File Dimensione Formato  
142363.pdf

accesso riservato

Descrizione: articolo principale
Tipologia: Publisher's version/PDF
Dimensione 189.08 kB
Formato Adobe PDF
189.08 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/501131
Citazioni
  • ???jsp.display-item.citation.pmc??? 14
  • Scopus 32
  • ???jsp.display-item.citation.isi??? 31
social impact